Patent SG-11201909955X-A (SG)
Title: Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
Inventor: DESAI PREETI
IPC: C07K16/46
Filed: 2018-05-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omit VIII °nolo oloionmll VIII VIII oimIE (10) International Publication Number WO 2018/204374 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/46 (2006.01) C07K 16/00 (2006.01) C07K 19/00 (2006.01) C07K 16/28 (2006.01) C12P 21/08 (2006.01) (21) International Application Number: PCT/US2018/030468 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/500,330 02 May 2017 (02.05.2017) US (71) Applicant: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (72) Inventors; and (71) Applicants (for US only): DESAI, Preeti, G. [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). SHI, Shuai [CN/US]; 6 Barberry Court, Whippa- ny, New Jersey 07981 (US). ANTOCHSHUK, Valentyn [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jer- sey 07033 (US). BURLAGE, Rubi [US/US]; 2000 Gal- loping Hill Road, Kenilworth, New Jersey 07033 (US). RAGHAVA, Smita [IN/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES Diffusion Interaction Parameter (K D ) Y 0.0 -- E —2.5- g —5.0- -7.5- 8 —10.0- c g o —15.0 L—arginine L histidine A Sodium chloride N O 40 I mM 70 I mM 100mM Concentration (mM) FIG.15 1-1 \" (57) : The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and C anti-LAG3 antibodies, and their use in treating various disorders. [Continued on next page] WO 2018/204374 Al MIDEDIMOMOIDEIRDERIHIMINIMIIHOHMEHOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))